Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its Treatment

被引：65

作者：

Farr, Katherina Podlekareva ^{[1
]}

Safwat, Akmal ^{[1
]}

机构：

[1] Aarhus Univ Hosp, Dept Oncol, Noerrebrogade 44, DK-8000 Aarhus, Denmark

来源：

CASE REPORTS IN ONCOLOGY | 2011年 / 4卷 / 01期

关键词：

Palmar-plantar erythrodysesthesia; Hand-foot syndrome; Pegylated liposomal doxorubicin;

D O I：

10.1159/000327767

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Palmar-plantar erythrodysesthesia (PPE), also called hand-foot syndrome, is a relatively common dermatologic toxic reaction associated with cytotoxic chemotherapy that can limit the use of such drugs. Definitive prevention and treatment strategies for PPE have not yet been established. We present a patient with recurrent ovarian cancer developing severe hand-foot syndrome after treatment with pegylated liposomal doxorubicin. A review of the relevant literature concerning pathophysiology, preventive measures and management of PPE is given. Electronic search was conducted using the Medline database for English-language records. The search terms used were 'palmar-plantar erythrodysesthesia', 'hand-foot syndrome', 'pegylated liposomal doxorubicin' and 'acral erythema'.

引用

页码：229 / 235

页数：7

共 15 条

[1]

Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer [J].

Charrois, GJR ;

Allen, TM .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2004, 1663 (1-2) :167-177

[2]

Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].

Gordon, AN ;

Fleagle, JT ;

Guthrie, D ;

Parkin, DE ;

Gore, ME ;

Lacave, AJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322

[3]

GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO

[4]

2-H

[5]

Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study [J].

Hackbarth, Mark ;

Haas, Norbert ;

Fotopoulou, Christina ;

Lichtenegger, Werner ;

Sehouli, Jalid .

SUPPORTIVE CARE IN CANCER, 2008, 16 (03) :267-273

[6]

Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma [J].

Hau, P ;

Fabel, K ;

Baumgart, U ;

Rümmele, P ;

Grauer, O ;

Bock, A ;

Dietmaier, C ;

Dietmaier, W ;

Dietrich, J ;

Dudel, C ;

Hübner, F ;

Jauch, T ;

Drechsel, E ;

Kleiter, I ;

Wismeth, G ;

Zellner, A ;

Brawanski, A ;

Steinbrecher, A ;

Marienhagen, J ;

Bogdahn, U .

CANCER, 2004, 100 (06) :1199-1207

[7]

Release of doxorubicin in sweat:: first step to induce the palmarplantar erythrodysesthesia syndrome? [J].

Jacobi, U ;

Waibler, E ;

Schulze, P ;

Sehouli, J ;

Oskay-Özcelik, G ;

Schmook, T ;

Sterry, W ;

Lademann, J .

ANNALS OF ONCOLOGY, 2005, 16 (07) :1210-1211

[8]

LEE S, 2007, P AN M AM SOC CLIN, V25, P9007

[9]

Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) [J].

Lorusso, D. ;

Di Stefano, A. ;

Carone, V. ;

Fagotti, A. ;

Pisconti, S. ;

Scambia, G. .

ANNALS OF ONCOLOGY, 2007, 18 (07) :1159-1164

[10]

Prevention strategies in palmar-plantar erythrodysesthesia onset: The role of regional cooling [J].

Mangili, G. ;

Petrone, M. ;

Gentile, C. ;

De Marzi, P. ;

Vigano, R. ;

Rabaiotti, E. .

GYNECOLOGIC ONCOLOGY, 2008, 108 (02) :332-335

← 1 2 →